Skip to content

CytoDyn Inc.: 10-Q filed 2019-01-09

What CytoDyn Inc. reported in its quarterly report filed 2019-01-09 (fiscal Q2 2019): 28 published measures, 81 facts as tagged in accession 0001193125-19-005378.

This filing

Form
10-Q (quarterly report)
Filed
2019-01-09
Fiscal period
fiscal Q2 2019
Accession
0001193125-19-005378 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CytoDyn Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-11-3020,390,953USD
At 2018-05-314,898,998USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-11-3028,454,877USD
At 2018-05-3118,056,969USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-11-30-8,063,924USD
At 2018-08-31-19,797,305USD
At 2018-05-31-13,157,971USD
At 2018-02-28-7,592,679USD
At 2017-11-30-12,790,510USD
At 2017-08-31-8,357,793USD
At 2017-05-31-1,103,234USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-11-30772,361USD
At 2018-05-311,231,445USD
At 2017-11-301,296,839USD
At 2017-05-311,775,583USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-09-01 to 2018-11-30-14,305,380USD91
2018-06-01 to 2018-11-30-28,718,950USD183
2018-06-01 to 2018-08-31-14,413,569USD92
2018-03-01 to 2018-05-31-9,623,623USD92
2017-12-01 to 2018-02-28-17,950,100USD90
2017-09-01 to 2017-11-30-10,947,685USD91
2017-06-01 to 2017-11-30-22,575,959USD183
2017-06-01 to 2017-08-31-11,628,273USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-06-01 to 2018-11-30-26,192,989USD183
2017-06-01 to 2017-11-30-12,889,820USD183

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2018-06-01 to 2018-11-302,262USD183

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-06-01 to 2018-11-3025,736,167USD183
2017-06-01 to 2017-11-3012,411,076USD183

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-06-01 to 2018-11-30-2,262USD183

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-11-30-201,858,345USD
At 2018-05-31-173,139,396USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2018-09-01 to 2018-11-302,826,919USD91
2018-06-01 to 2018-11-302,826,919USD183
2017-06-01 to 2018-05-310USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-11-3010,127USD
At 2018-05-3111,228USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2018-06-01 to 2018-11-301,510,486USD183
2017-06-01 to 2017-11-30529,617USD183

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-09-01 to 2018-11-30-15,687,790USD91
2018-06-01 to 2018-11-30-29,176,486USD183
2017-09-01 to 2017-11-30-10,775,051USD91
2017-06-01 to 2017-11-30-20,582,050USD183

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-11-303,927,875USD
At 2018-05-313,320,627USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-09-01 to 2018-11-301,726,585USD91
2018-06-01 to 2018-11-301,904,973USD183
2017-09-01 to 2017-11-301,002,656USD91
2017-06-01 to 2017-11-302,462,049USD183

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-11-3023,982,761USD
At 2018-05-3116,733,237USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-11-3018,852,414USD
At 2018-05-3115,841,859USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2018-11-3016,416,962USD
At 2018-05-311,531,154USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-09-01 to 2018-11-3015,687,790USD91
2018-06-01 to 2018-11-3029,176,486USD183
2017-09-01 to 2017-11-3010,775,051USD91
2017-06-01 to 2017-11-3020,582,050USD183

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-09-01 to 2018-11-3012,869,244USD91
2018-06-01 to 2018-11-3024,337,910USD183
2017-09-01 to 2017-11-309,077,172USD91
2017-06-01 to 2017-11-3017,225,348USD183

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-11-30290,649,949shares
At 2018-05-31216,722,779shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-11-30193,503,678USD
At 2018-05-31159,764,611USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2018-11-305,596,974USD
At 2018-08-315,073,758USD
At 2018-05-310USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2018-11-3016,452,951USD
At 2018-05-311,567,143USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2018-09-01 to 2018-11-30-17,132,299USD91
2018-06-01 to 2018-11-30-31,545,869USD183
2017-09-01 to 2017-11-30-10,947,685USD91
2017-06-01 to 2017-11-30-22,575,959USD183

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-09-01 to 2018-11-302,663,745USD91
2018-06-01 to 2018-11-304,594,804USD183
2017-09-01 to 2017-11-301,608,743USD91
2017-06-01 to 2017-11-303,178,420USD183

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2018-09-01 to 2018-11-302,826,919USD91
2018-06-01 to 2018-11-30-2,826,919USD183

Inspect the source

Entity
CytoDyn Inc. / CIK 0001175680
Captured
2026-09-20T07:44:48.635Z
SEC response SHA-256
ccd180f98f5bd324896d13ce785229f8b7185dbfcf88932cc316c9c53bdaba90

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175680.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))